Good science behind hepatitis C virus antiviral drug development: Necessary but not sufficient

Hepatology

Volumn 46, Issue 5, 2007, Pages 1317-1318

  Pappas, S Chris ^a,b  

^a Texas Childrens Cancer Center   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG 10101; PEGINTERFERON; RIBAVIRIN; VALOPICITABINE; ALPHA INTERFERON; TOLL LIKE RECEPTOR 9;

ANTIVIRAL THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG COST; HEALTH CARE QUALITY; IN VITRO STUDY; PLASMACYTOID DENDRITIC CELL; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; VIRUS LOAD;

EID: 36349031101     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22053     Document Type: Editorial

References (9)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
2. McHutchinson JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44:411-421.
3. McHutchinson JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, et al. A phase 1B, randomized, double-blind, does escalation trial of CPG 10101 in patients with chronic hepatitis C virus. HEPATOLOGY 2007; 46. DOI 10.1002/hep.21773.
4. Development discontinued for ANA975, an early stage compound for treatment of hepatitis C virus infection [press release]. San Diego, CA: Anadys Pharmaceuticals Inc.; July 26, 2007. Available at: http://ir.anadyspharma.com/ phoenix.zhtml?c=148908&p=irol-newsArticle&ID=1032389&highlight. Accessed September 24, 2007.
5. Valopicitabine development program placed on clinical hold in the United States [press release]. Cambridge, MA: Idenix Pharmaceuticals Inc.; July 13, 2007. Available at: http://ir.idenix.com/phoenix.zhtml?c=131556&p=irol- newsArticle&ID=1025874&highlight. Accessed September 24, 2007.
6. Potential safety issue identified in ongoing phase 2 clinical study of HCV-796 [press release]. Exton, PA: ViroPharma Inc.; August 10, 2007. Available at: http://www.viropharma.com/therapeutic/hcv796.asp. Accessed September 24, 2007.
7. U.S. Food and Drug Administration. Summary Minutes of the Antiviral Drug Advisory Committee Meeting, October 19-20, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4250m1.pdf. Accessed September 24, 2007.
8. Northrup J. The pharmaceutical sector. In: Lawton RB, ed. The Business of Healthcare Innovation. Cambridge, UK: Cambridge University Press; 2005:27-102.
9. Chemmanur AT, Wu GY. Drug evaluation: Albuferon-alpha - An antiviral interferon-alpha/albumin fusion protein. Curr Opin Investig Drugs 2006;7:750-758.